ArticleJournal of Cancer2025
An integrated analysis identified mitochondrial ribosomal protein MRPL3 as a potential prognostic biomarker and therapeutic target in pancreatic cancer.
Article in Journal of Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MRPL3 enhances mitochondrial function via the TOMM40/PGC-1α/TFAM axis to drive early recurrence in hepatocellular carcinoma.Cell death & disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondria play a crucial role in tumor metabolism. Mitochondrial ribosomal protein L3 (MRPL3) is a core component of the mitochondrial ribosome. However, its role in pancreatic cancer (PC) remains unclear. We investigated the biological functions and underlying mechanisms of MRPL3 in PC. The expression of MRPL3 was analyzed using public databases. Prognostic significance was evaluated using Kaplan-Meier survival analysis and univariate/multivariate Cox regression. Functional enrichment analysis was performed to identify MRPL3-associated signaling pathways. In addition, immune cell infiltration and tumor mutational burden (TMB) analyses were conducted to explore the relationship between MRPL3 expression and the tumor microenvironment. Tumor immune dysfunction and exclusion (TIDE) scores and drug sensitivity analyses were used to assess the therapeutic implications of MRPL3. Western blotting and immunohistochemistry (IHC) were performed to validate MRPL3 expression and evaluate their prognostic significance in clinical PC samples.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.